Related Experiment Videos
Increased levels of urinary adenosine deaminase binding protein in children treated with cisplatin or methotrexate
Insights
Urinary adenosine deaminase binding protein (ABP) levels increased in children receiving nephrotoxic cancer drugs like cisplatin or methotrexate. This finding suggests ABP may help detect early kidney damage from these treatments.
Area of Science:
- Nephrology
- Oncology
- Biochemistry
Background:
- Solid tumors in children often require chemotherapy with nephrotoxic agents.
- Cisplatin and methotrexate are common chemotherapy drugs known to cause kidney damage.
- Early detection of renal tubular damage is crucial for managing treatment toxicity.
Purpose of the Study:
- To investigate urinary adenosine deaminase binding protein (ABP) as a biomarker for early renal tubular damage.
- To assess ABP excretion in children receiving cisplatin or methotrexate therapy.
- To correlate ABP levels with other urinary enzyme markers of kidney injury.
Main Methods:
- Enzyme immunoassay was used to measure urinary ABP levels.
- Urine specimens were collected from seven children with solid tumors undergoing chemotherapy.
- Urinary N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase levels were also measured.
Main Results:
- Urinary ABP excretion uniformly increased within 3 days of cisplatin or methotrexate administration.
- Elevated ABP levels often coincided with increased excretion of other urinary enzymes.
- ABP levels remained elevated in alkaline urine during methotrexate therapy, unlike enzyme activities.
Conclusions:
- Urinary ABP is a sensitive indicator of early renal tubular damage induced by nephrotoxic chemotherapy.
- Immunochemical measurement of urinary ABP may serve as a valuable adjunct in clinical studies of drug-induced nephrotoxicity.
- ABP monitoring can aid in the early detection and management of kidney damage in pediatric cancer patients.
Abstract:
Levels of adenosine deaminase binding protein (ABP), a renal tubular cell antigen, were determined by enzyme immunoassay in urine specimens from seven children with solid tumors who were receiving the recognized nephrotoxins cisplatin or methotrexate. ABP excretion was uniformly increased within the first 3 days after administration of either drug. Elevated ABP levels were usually accompanied by increased excretion of the urinary enzymes N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase. In alkaline urine specimens associated with methotrexate therapy, ABP levels were increased whereas enzyme activities appeared to be unstable. Hence, immunochemical measurement of urinary ABP levels may be adjunctively useful for clinical studies of renal tubular damage.